Highest-materiality recent filing
JNJ Q1 adj. EPS $2.70 (down 1.4% YoY); raises dividend 3.1% to $1.34/qtr
Q1 revenue $24.06B, up 9.9% YoY (operational growth 6.4%, currency 3.5%).
JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46
Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).
JNJ reports Q3 adjusted EPS $2.80; plans to spin off Orthopaedics as DePuy Synthes
Q3 revenue $23,993M (+6.8% YoY); GAAP EPS $2.12, adjusted EPS $2.80 (+15.7% YoY).
JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)
Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).
JNJ Q1 adj EPS $2.77 (+2.2%), revenue $21.9B; dividend +4.8% to $1.30
GAAP net earnings $11.0B ($4.54 diluted EPS) vs $3.3B ($1.34), boosted by $7.3B other income.
Bankruptcy court denies J&J's Red River Talc prepackaged plan; $7B reserve reversed
U.S. Bankruptcy Court for Southern District of Texas denied confirmation of Red River Talc LLC's prepackaged plan on March 31, 2025.
Johnson & Johnson completes €4B multi-tranche euro note offering
Issued €600M 2.700% Notes due 2029, €700M 3.050% Notes due 2033, and €1B 3.350% Notes due 2037.
Issued $750M 4.500% notes due 2027, $750M 4.550% notes due 2028, and $1B 4.700% notes due 2030.
JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04
Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.
Worldwide sales $22.47B (+5.2% reported, +6.3% operational); MedTech up 5.8%, Innovative Medicine up 4.9%.
Red River Talc LLC filed voluntary prepackaged Chapter 11 in Southern District of Texas.
J&J Q2 revenue up 4.3% but GAAP EPS falls 5.9%; adjusted EPS rises 10.2%
Q2 2024 revenue $22.4B, +4.3% YoY; GAAP diluted EPS $1.93, -5.9% YoY; adjusted diluted EPS $2.82, +10.2% YoY.
Johnson & Johnson fully divests remaining Kenvue stake via debt-for-equity exchange
On May 17, 2024, JNJ exchanged its remaining 182.3M Kenvue shares for $3.6B commercial paper, eliminating its Kenvue ownership.
JNJ proposes $6.475B talc settlement plan; Q1 GAAP EPS cut to $1.34
Proposed plan pays $6.475B present value ($8.4B nominal over 25 years) to resolve all ovarian cancer cosmetic talc claims.
JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter
Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%
D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23 rd that he will join Goldman Sachs as a Partner.
On September 10, 2024, D. S. Davis retired as a Director of Johnson & Johnson after the successful transition of Audit Committee Chair responsibilities to D. Adamczyk.
On August 26, 2024, Johnson & Johnson (the Company) issued a press release announcing that Peter M. Fasolo, Executive Vice President, Chief Human Resources Officer (CHRO), has elected to retire.
Max materiality 0.90 · Median 0.65 · Most common event earnings